Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2020

01-08-2020 | Infliximab | Editorial

Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch?

Author: Frank I. Scott

Published in: Digestive Diseases and Sciences | Issue 8/2020

Login to get access

Excerpt

Biologic therapies have markedly changed the treatment landscape in inflammatory bowel disease (IBD). Patients with Crohn’s disease (CD) and ulcerative colitis (UC) now have access to five tumor necrosis factor-alpha (anti-TNF) antibodies, two leukocyte adhesion inhibitors, and a monoclonal antibody targeting the common p40 subunit of interleukins (IL) 12 and 23. Multiple pharmacotherapies exploiting these and other molecular targets are currently being developed. Emerging data suggest that these biologic therapies may reduce rates of hospitalization and surgery in IBD. …
Literature
1.
Yu H, MacIsaac D, Wong JJ, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47:364–370.CrossRef
2.
Park KT, Ehrlich OG, Allen JI, et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & colitis foundation. Inflamm Bowel Dis. 2020;26:1–10.CrossRef
3.
McCamish M, Yoon W, McKay J. Biosimilars: biologics that meet patients’ needs and healthcare economics. Am J Manag Care. 2016;22:S439–S442.PubMed
4.
Scott FI, Lichtenstein GR. Biosimilars in the treatment of inflammatory bowel disease: supporting evidence in 2017. Curr Treat Opt Gastroenterol. 2018;16:147–164.CrossRef
5.
Dutcher SK, Fazio-Eynullayeva E, Eworuke E, et al. Understanding utilization patterns of biologics and biosimilars in the USA to support postmarketing studies of safety and effectiveness. Pharmacoepidemiol Drug Saf. 2019.
6.
Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;45:1043–1057.CrossRef
7.
Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316.CrossRef
8.
9.
Volkers A, Jansen JM. Similar trial—efficacy of infliximab-biological in patients with inflammatory bowel disease in remission—a randomized controlled, double blind, phase 4 non-inferiority trial. United Eur Gastroenterol J. 2017;5:p0409.
10.
Ho Kim Y, Ye BD, Pesegova M, et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab (INX) in patients with active Crohn’s disease: early efficacy and safety results. Gastroenterology. 2017;152:S65.CrossRef
11.
Kaplan GG, Ma C, Seow CH, Kroeker KI, Panaccione R. The argument against a biosimilar switch policy for infliximab in patients with inflammatory bowel disease living in Alberta. J Can Assoc Gastroenterol. 2020.
Metadata
Title
Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch?
Author
Frank I. Scott
Publication date
01-08-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06283-6

Other articles of this Issue 8/2020

Digestive Diseases and Sciences 8/2020 Go to the issue

Brief Communication

Sex Differences in Authorship of Major Gastroenterology Society Guidelines and Technical Reviews

Editorial

Is Tissue Really the Issue? How the Polyp Detection Rate May Be a Good Enough Quality Measure Among Trainees

DDS AUTHOR PROFILES

Author Spotlight: Nikki Duong

Original Article

MiR-525-5p Repressed Metastasis and Anoikis Resistance in Cervical Cancer via Blocking UBE2C/ZEB1/2 Signal Axis

DDS–SIRC COOPERATIVE CONFERENCES

There Is a Great Future in Plastics: Personalized Approach to the Management of Hilar Cholangiocarcinoma Using a 3-D-Printed Liver Model

Original Article

Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits